Tvardi Therapeutics is trading at $1.02, down 5.09%, with no clear company-specific catalyst identified during the October 9 session.
- The latest listed company press release is dated September 24 and concerns preclinical ulcerative-colitis data, not a new October 9 announcement.
- The supplied biotech-sector trend is positive, with XBI up 2.50%; available evidence does not establish a market or sector cause for the decline.